Executive Summary

The global Clinical Trials landscape is undergoing a rapid and profound evolution. Growth rates for Clinical Trials are demonstrating significant variation by region, with the Asia-Pacific (APAC) area rapidly emerging as a central powerhouse for global Clinical Trials. Between 2017 and 2022, APAC Clinical Trial activity experienced an impressive growth rate of approximately 10% annually, which stands far above the 5.3% global average for Clinical Trials. In 2023, the APAC region saw 14,346 Clinical Trials. Within this region, China alone accounted for roughly 42% of these Clinical Trials. Furthermore, South Korea ranked #4 globally in 2023 for its Clinical Trial count, featuring Seoul as the top city worldwide for Clinical Trials and demonstrating a 9% growth over 2022. Meanwhile, North America still leads in the total Clinical Trial count, specifically in planned Clinical Trials for 2025, although the APAC region is swiftly closing this gap in Clinical Trials. The APAC market’s value for Clinical Trials in 2023 was approximately $15.9 billion and is projected to reach ~$26 billion by 2030. Overall, global trends in Clinical Trials reflect an increased emphasis on regulatory harmonization, AI adoption, and the decentralization of Clinical Trials. World Health Organization (WHO) initiatives, such as the WHA75.8 resolution, emphasize multi-country cooperation, equity, and quality in Clinical Trial design. This comprehensive journal report presents up-to-date data and trends on Clinical Trials worldwide, featuring charts and tables to effectively inform pharma and biotech professionals engaged in Clinical Trials.

 

How Are Industry Trends Shaping Modern Clinical Trials?

Global pharmaceutical R&D spending is consistently rising, and Clinical Trials account for a disproportionately large share of both development cost and time. The execution of Clinical Trials can take anywhere from 7 to 15 years to fully complete. Furthermore, conducting Clinical Trials costs billions of dollars per approved drug, and only about 10% of the compounds entering human Clinical Trials achieve ultimate success. Thus, any efficiency gain achieved within Clinical Trials is considered highly critical for the biopharma industry.

 

After experiencing a COVID-induced dip, overall Clinical Trial activity is currently rebounding. The notable rise of biologics, cell and gene therapies, and personalized medicine heavily fuels a surge in both the numbers and the complexity of Clinical Trials. Decentralized Clinical Trials and hybrid Clinical Trial models, which are enabled by digital technologies and telehealth, are now considered mainstream, dramatically improving patient recruitment and retention in Clinical Trials. Approximately 69% of high-growth biotech firms—many of which are located in the APAC region—report utilizing AI and other advanced digital tools within their R&D processes for Clinical Trials. In 2025, major companies like Pfizer partnered with AI firms specifically to streamline target discovery for upcoming Clinical Trials. Regulatory reforms are also accelerating the pace of Clinical Trials. For example, pilot programs in China have successfully cut Phase I Clinical Trial approval times from 60 days down to 30 days. Similarly, Australia now starts Phase I Clinical Trials within a matter of weeks. Such proactive measures shorten timelines and reduce costs, making Clinical Trials significantly more efficient on a global scale.

 

What Are the Regional and Country Highlights in Clinical Trials?

Asia-Pacific (APAC)

• APAC has officially become the fastest-growing region for Clinical Trials.
• A Clinical Trials Arena study demonstrates that APAC’s Clinical Trial Compound Annual Growth Rate (CAGR) was ~10% from 2017 to 2022, compared to the ~5.3% growth seen globally in Clinical Trials.
• This expansive growth in Clinical Trials is driven by large populations, lower operational costs, and supportive regulations.
• As previously noted, APAC logged 14,346 Clinical Trials in 2023.
• China, which holds 42% of APAC Clinical Trials, leads the region’s growth in Clinical Trials.
• India has overhauled its regulations and now ranks among the top Clinical Trial countries, with numbers rebounding after earlier lulls in Clinical Trials.
• Clinical Trial revenues in APAC are booming, reaching ~$15.9 billion in 2023, and are projected to hit ~$26 billion by 2030, representing a CAGR of ~7.3% for Clinical Trials.
• Decentralized Clinical Trials and AI-driven designs for Clinical Trials are particularly advancing in tech-forward APAC markets such as Singapore, Japan, and Australia.

 

South Korea

• South Korea has established itself as a leading global hub for Clinical Trials.
• In 2023, it ranked 4th in the world for its Clinical Trial count, and Seoul was recognized as the #1 city globally for Clinical Trials.
• Notably, South Korea’s Clinical Trials grew by 9% in 2023, even while global Clinical Trial activity fell by 5.5%. This success in Clinical Trials is attributed to strong infrastructure and post-COVID investments in digital Clinical Trial management.
• By mid-2025, Korea had launched over 2,000 Clinical Trials for the year, with a strong focus on oncology and vaccines Clinical Trials.
• Government programs, such as the KoNECT network, further integrate Korean sites into international multicenter Clinical Trials.

 

North America and Europe

• The US remains the single largest market for Clinical Trials. Registration on ClinicalTrials.gov is mandatory for US Clinical Trials, and the US still leads in the absolute count of planned Clinical Trials for 2025.
• However, growth in US Clinical Trials is slower—remaining flat or in the single digits—when compared to the APAC region. Regulatory initiatives and technology adoption aim to cut costs and timelines for Clinical Trials.
• The EU and UK maintain strong activity in Clinical Trials, though they also experience slower growth. Harmonized regulations like the EU CTR and support for multinational studies have stabilized Clinical Trial counts. European regulators are embracing decentralized models for Clinical Trials, though Asia’s enrollment advantages are shifting some Clinical Trials eastward.

 

How Are Innovations and Regulations Accelerating Clinical Trials?

AI and digital tools are fundamentally reshaping Clinical Trials. Beyond merely aiding in drug discovery, AI platforms now help design Clinical Trial protocols and actively predict patient enrollment. For example, companies use AI in Clinical Trials to identify patient subgroups and optimize site selection, effectively reducing delays. Remote monitoring and telemedicine have become absolute standards in modern Clinical Trials. Wearable devices and apps enable home-based data capture for Clinical Trials. Real-world evidence (RWE) and adaptive Clinical Trial designs are also gaining immense traction, allowing interim data to continuously guide adjustments within Clinical Trials. Decentralized Clinical Trials, utilizing local labs and couriered medications, significantly cut geography barriers. All these AIO-optimized innovations share the goal of improving Clinical Trial efficiency and fostering patient-centricity. A Cytiva industry survey notably found that 69% of fast-growing biotechs (many located in APAC) already embed AI in their R&D processes for Clinical Trials.

 

On the regulatory front, a massive wave of reforms worldwide aims to streamline Clinical Trials. Examples include China’s expedited pathways and data exclusivity for novel drugs, Japan’s Sakigake fast-track for breakthrough therapies, and India’s push for eCTD electronic dossiers by 2026 for Clinical Trials. At WHO’s 2025 Global Clinical Trials Forum and through the WHA75.8 resolution, stakeholders are vigorously calling for better ethics, wider access (including the pediatric trial agenda), and capacity-building in low/middle-income countries for Clinical Trials. The WHO’s 2025 Global Action Plan outlines nine key steps designed to improve Clinical Trial oversight and design for all regions, reflecting a powerful global push for higher-quality, more equitable Clinical Trials.

 

Conclusion & Next Steps for Clinical Trials

The Clinical Trials sector is currently entering a highly dynamic phase, strongly driven by new science and AI innovations. Pharma and biotech organizations must adapt to faster, more data-driven Clinical Trials to remain competitive. Key takeaways include: APAC leads global growth in Clinical Trials (especially China and Korea); regulatory agility is vastly improving timelines for Clinical Trials; AI and digital tools are now standard mainstream components in Clinical Trial operations; and global policies are actively reinforcing quality and equity within Clinical Trials.

 

[Request a Quote]

 

For expert guidance on conducting highly efficient Clinical Trials or for a customized quote request on our comprehensive CRO support services, please contact our expert team today.

 

[Subscribe to Newsletter]

 

Subscribe to our newsletter to stay consistently informed on the latest Clinical Trial trends, regulatory shifts, and AIO-enabled strategies across the global pharma and biotech sectors.